Advertisement

Clinical Oral Investigations

, Volume 23, Issue 3, pp 1031–1040 | Cite as

Metabolomics profiling of cleidocranial dysplasia

  • Zhaoqiang Zhang
  • Kefeng Li
  • Mengdie Yan
  • Qiuping Lin
  • Jiahong Lv
  • Ping Zhu
  • Yue XuEmail author
Original Article
  • 184 Downloads

Abstract

Objectives

Cleidocranial dysplasia (CCD) is a rare autosomal-dominantly inherited skeletal dysplasia that is predominantly associated with heterozygous mutations of RUNX2. However, no information is available regarding metabolic changes associated with CCD at present.

Materials and methods

We analyzed members of a CCD family and checked for mutations in the RUNX2 coding sequence using the nucleotide BLAST program. The 3D protein structure of mutant RUNX2 was predicted by I-TASSER. Finally, we analyzed metabolites extracted from plasma using LC-MS/MS.

Results

We identified a novel mutation (c.1061insT) that generates a premature termination in the RUNX2 coding region, which, based on protein structure prediction models, likely alters the protein’s function. Interestingly, metabolomics profiling indicated that 30 metabolites belonging to 13 metabolic pathways were significantly changed in the CCD patients compared to normal controls.

Conclusions

The results highlight interesting correlations between a RUNX2 mutation, metabolic changes, and the clinical features in a family with CCD. The results also contribute to our understanding of the pathogenetic processes underlying this rare disorder.

Clinical relevance

This study provides the first metabolomics profiling in CCD patients, expands our insights into the pathogenesis of the disorder, may help in diagnostics and its refinements, and may lead to novel therapeutic approaches to CCD.

Keywords

CCD Metabolic changes RUNX2 Mutation Patients Protein structure 

Notes

Funding

The work was supported by the Southern Medical University (grants PY2017N036); National Natural Science Foundation of China (grants 81571020 and 81771124); Natural Science Foundation of Guangdong Province (grants 2015A030313179).

Compliance with ethical standards

Conflict of interest

Z.Z. declares that he has no conflict of interest. K.L. declares that he has no conflict of interest. M.Y. declares that he has no conflict of interest. Q.L. declares that he has no conflict of interest. J.L. declares that he has no conflict of interest. P.Z. declares that he has no conflict of interest. Y.X. declares that he has no conflict of interest.

Ethical approval

All procedures performed in our study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Cooper SC, Flaitz CM, Johnston DA, Lee B, Hecht JT (2001) A natural history of cleidocranial dysplasia. Am J Med Genet 104(1):1–6CrossRefGoogle Scholar
  2. 2.
    Mundlos S (1999) Cleidocranial dysplasia: clinical and molecular genetics. J Med Genet 36(3):177–182Google Scholar
  3. 3.
    Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, Owen MJ, Mertelsmann R, Zabel BU, Olsen BR (1997) Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89(5):773–779CrossRefGoogle Scholar
  4. 4.
    Lee B, Thirunavukkarasu K, Zhou L, Pastore L, Baldini A, Hecht J, Geoffroy V, Ducy P, Karsenty G (1997) Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat Genet 16(3):307–310CrossRefGoogle Scholar
  5. 5.
    Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G (1997) Osf2/Cbfa1, a transcriptional activator of osteoblast differentiation. Cell 89(5):747–754CrossRefGoogle Scholar
  6. 6.
    Yoshida CA, Yamamoto H, Fujita T, Furuichi T, Ito K, Inoue K, Yamana K, Zanma A, Takada K, Ito Y, Komori T (2004) Runx2 and Runx3 are essential for chondrocyte maturation, and Runx2 regulates limb growth through induction of Indian hedgehog. Genes Dev 18(8):952–963CrossRefGoogle Scholar
  7. 7.
    Li Y, Xiao Z (2007) Advances in Runx2 regulation and its isoforms. Med Hypotheses 68(1):169–175CrossRefGoogle Scholar
  8. 8.
    Thirunavukkarasu K, Mahajan M, McLarren KW, Stifani S, Karsenty G (1998) Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfβ. Mol Cell Biol 18(7):4197–4208CrossRefGoogle Scholar
  9. 9.
    Zhang YW, Yasui N, Ito K, Huang G, Fujii M, Hanai J, Nogami H, Ochi T, Miyazono K, Ito Y (2000) A RUNX2/PEBP2αA/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci U S A 97(19):10549–10554CrossRefGoogle Scholar
  10. 10.
    Afzal F, Pratap J, Ito K, Ito Y, Stein JL, van Wijnen AJ, Stein GS, Lian JB, Javed A (2005) Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol 204(1):63–72CrossRefGoogle Scholar
  11. 11.
    Zelzer E, Glotzer DJ, Hartmann C, Thomas D, Fukai N, Soker S, Olsen BR (2001) Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 106(1–2):97–106CrossRefGoogle Scholar
  12. 12.
    Zaidi SK, Pande S, Pratap J, Gaur T, Grigoriu S, Ali SA, Stein JL, Lian JB, van Wijnen AJ, Stein GS (2007) Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci U S A 104(50):19861–19866CrossRefGoogle Scholar
  13. 13.
    Mak IW, Cowan RW, Popovic S, Colterjohn N, Singh G, Ghert M (2009) Upregulation of MMP-13 via Runx2 in the stromal cell of giant cell tumor of bone. Bone 45(2):377–386CrossRefGoogle Scholar
  14. 14.
    Teplyuk NM, Zhang Y, Lou Y, Hawse JR, Hassan MQ, Teplyuk VI, Pratap J, Galindo M, Stein JL, Stein GS, Lian JB, van Wijnen AJ (2009) The osteogenic transcription factor runx2 controls genes involved in sterol/steroid metabolism, including CYP11A1 in osteoblasts. Mol Endocrinol 23(6):849–861CrossRefGoogle Scholar
  15. 15.
    Sawai CM, Sisirak V, Ghosh HS, Hou EZ, Ceribelli M, Staudt LM, Reizis B (2013) Transcription factor Runx2 controls the development and migration of plasmacytoid dendritic cells. J Exp Med 210(11):2151–2159CrossRefGoogle Scholar
  16. 16.
    Stein GS, Lian JB, van Wijnen AJ, Stein JL, Montecino M, Javed A, Zaidi SK, Young DW, Choi JY, Pockwinse SM (2004) Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 23(24):4315–4329CrossRefGoogle Scholar
  17. 17.
    Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, Wozney JM, Kim EG, Choi JY, Ryoo HM, Bae SC (2000) Runx2 is a common target of transforming growth factor β1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 20(23):8783–8792CrossRefGoogle Scholar
  18. 18.
    Putri SP, Nakayama Y, Matsuda F, Uchikata T, Kobayashi S, Matsubara A, Fukusaki E (2013) Current metabolomics, practical applications. J Biosci Bioeng 115(6):579–589CrossRefGoogle Scholar
  19. 19.
    Yuan M, Breitkopf SB, Yang X, Asara JM (2012) A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc 7(5):872–881CrossRefGoogle Scholar
  20. 20.
    Zhang C, Zheng S, Wang Y, Zhao Y, Zhu J, Ge L (2010) Mutational analysis of RUNX2 gene in Chinese patients with cleidocranial dysplasia. Mutagenesis 25(6):589–594CrossRefGoogle Scholar
  21. 21.
    Wang S, Zhang S, Wang Y, Chen Y, Zhou L (2013) Cleidocranial dysplasia syndrome, clinical characteristics and mutation study of a Chinese family. Int J Clin Exp Med 6(10):900–907Google Scholar
  22. 22.
    Otto F, Kanegane H, Mundlos S (2002) Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat 19(1):209–216CrossRefGoogle Scholar
  23. 23.
    Ott CE, Leschik G, Trotier F, Brueton L, Brunner HG, Brussel W, Guillen-Navarro E, Haase C, Kohlhase J, Kotzot D, Lane A, Lee-Kirsch MA, Morlot S, Simon ME, Steichen-Gersdorf E, Tegay DH, Peters H, Mundlos S, Klopocki E (2010) Deletions of the RUNX2 gene are present in about 10% of individuals with cleidocranial dysplasia. Hum Mutat 31(8):1587­1593CrossRefGoogle Scholar
  24. 24.
    Baumert U, Golan I, Redlich M, Aknin JJ, Muessig D (2005) Cleidocranial dysplasia, molecular genetic analysis and phenotypic-based description of a middle European patient group. Am J Med Genet 139((2):78–85CrossRefGoogle Scholar
  25. 25.
    Bufalino A, Paranaíba LM, Gouvêa AF, Gueiros LA, Martelli-Júnior H, Junior JJ, Lopes MA, Graner E, De Almeida OP, Vargas PA, Coletta RD (2012) Cleidocranial dysplasia, oral features and genetic analysis of 11 patients. Oral Dis 18(2):184–190CrossRefGoogle Scholar
  26. 26.
    Singh A, Goswami M, Pradhan G, Han MS, Choi JY, Kapoor S (2015) Cleidocranial dysplasia with normal clavicles, a report of a novel genotype and a review of seven previous cases. Mol Syndromol 6(2):83–86CrossRefGoogle Scholar
  27. 27.
    Madsen R, Lundstedt T, Trygg J (2010) Chemometrics in metabolomics—a review in human disease diagnosis. Anal Chim Acta 659(1–2):23–33CrossRefGoogle Scholar
  28. 28.
    Chang DJ, Ji C, Kim KK, Casinghino S, McCarthy TL, Centrella M (1998) Reduction in transforming growth factor b receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J Biol Chem 273(9):4892–4896CrossRefGoogle Scholar
  29. 29.
    Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA, Frenkel B (2010) Runx2 transcriptome of prostate cancer cells, insights into invasiveness and bone metastasis. Mol Cancer 9:258CrossRefGoogle Scholar
  30. 30.
    Kilbey A, Terry A, Jenkins A, Borland G, Zhang Q, Wakelam MJ, Cameron ER, Neil JC (2010) Runx regulation of sphingolipid metabolism and survival signaling. Cancer Res 70(14):5860–5869CrossRefGoogle Scholar
  31. 31.
    Choe M, Brusgard JL, Chumsri S, Bhandary L, Zhao XF, Lu S, Goloubeva OG, Polster BM, Fiskum GM, Girnun GD, Kim MS, Passaniti A (2015) The RUNX2 transcription factor negatively regulates SIRT6 expression to Alter glucose metabolism in breast Cancer cells. J Cell Biochem 116(10):2210–2226CrossRefGoogle Scholar
  32. 32.
    Adhami M, Ghori-Javed FY, Chen H, Gutierrez SE, Javed A (2011) Runx2 regulates the gene network associated with insulin signaling and energy homeostasis. Cells Tissues Organs 194(2–4):232–237CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Zhaoqiang Zhang
    • 1
  • Kefeng Li
    • 2
  • Mengdie Yan
    • 3
    • 4
  • Qiuping Lin
    • 3
  • Jiahong Lv
    • 3
  • Ping Zhu
    • 5
  • Yue Xu
    • 3
    Email author
  1. 1.Department of Oral and Maxillofacial Surgery, Stomatological HospitalSouthern Medical UniversityGuangzhouPeople’s Republic of China
  2. 2.San Diego (UCSD) School of MedicineUniversity of CaliforniaSan DiegoUSA
  3. 3.Department of Orthodontics, Guanghua School of Stomatology, Hospital of StomatologySun Yat-sen UniversityGuangzhouPeople’s Republic of China
  4. 4.Department of Orthodontics, Stomatological HospitalSouthern Medical UniversityGuangzhouPeople’s Republic of China
  5. 5.Department of Oral and Maxillafacial SurgeryGuanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen UniversityGuangzhouPeople’s Republic of China

Personalised recommendations